Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis un­veils 'US-first' strat­e­gy ahead of San­doz spin­off

Weeks af­ter an­nounc­ing the spin­off of gener­ics arm San­doz, Vas Narasimhan paints a pic­ture of the new, slim­mer No­var­tis — with a “US-first mind­set,” he said at an in­vestor event on Thurs­day.

The CEO un­veiled am­bi­tious plans to be­come a top-five play­er in the US by 2027 at No­var­tis’ “Meet the Man­age­ment” event in Basel, Switzer­land, which means ramp­ing up clin­i­cal tri­als in the states and “build­ing ca­pa­bil­i­ty and tal­ent, among oth­er things.” The com­pa­ny’s al­so shoot­ing for a top-three rank­ing in Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.